http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2768295-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d79362493392629399a529d819cdccd8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0821 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0823 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-097 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2010-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b9ae4ea7d5d50ba8d826c2619157b67 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8287d2b825d7fe5fe485f361b6fd40b |
| publicationDate | 2020-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2768295-T3 |
| titleOfInvention | Prodrugs of heteroaromatic compounds |
| abstract | A compound of Formula I: ** Formula ** or a pharmaceutically acceptable salt thereof, for use in subcutaneous or intramuscular injection therapy to administer a parent drug compound of Formula II, ** Formula ** wherein: each of X1 a X4 is independently N or CR, provided that at least one of X1-X4 is CR; each R is independently hydrogen, or optionally substituted aliphatic, aromatic, or heteroaromatic; or any 2 R groups can also be taken in conjunction with the carbon atoms to which they are attached to form a fused ring; R5 is selected from -C (R8) (R9) -OC (O) OR10 and -C (R8) (R9) -OC (O) R10; R8 and R9 are each independently hydrogen or aliphatic; or R8 is -C (O) H or -CH (OH) CH2OH and R is hydrogen; and R10 is C7-C24 alkyl, C7-C24 alkenyl or C7-C24 alkynyl; and / or where X1 to X4 are such that the parent drug compound of formula II is mepiprazole, dexmedetomidine, albendazole, carbendazole, cyclobendazole, mebendazole, thiabendazole, almotriptan, dolasetron, eletriptan, lisuride, naratriptan, rizatriptan, zytriptan, sumatriptan, sumatriptan , ergotamine, alosetron, delavirdine, atevirdine, bopindolol, bucindolol, candesartan, deserpidine, mibefradil, ergoloid mesylate, indoramine, irbesartan, mepindolol, olmesartan, reserpine, rescinamine, losartanberg, reserpine, carotropinberg, rescinbergasrtolineosartubine, sirolinascine, ratamineosartubine pergolide, bromocriptine, terguride, ambufilin, cimetidine, lansoprazole, omeprazole, pantaprozole, rabeprazole, cefatrizin, daptomycin, ergonovine, methylergonovine, etodolac, liarozole, pemetrexed, thiamiprine, vinistundaliine, vincritine, invinistundaline, vincritine, vinistundaliine, invinistine, inoclindespertine, vinistundaliine, roxindole, pemirolast, tazanolast, traxanox, pimobendan, sulmazol, pranlukast, ramosetron, tropisetró n, alizapride, bendazole, tadalafil, allopurinol, azathioprine, yohimbine, conivaptan, adrenoglomerulotropin, octreotide, somatostatin, exenatide, teriparatide, leuprorelin, or goserelin. |
| priorityDate | 2010-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 427.